PRAX vs PTCT
PRAX: A clinical-stage CNS biotech translating genetic epilepsy insights into precision therapies for neurological disorders via proprietary small-molecule and antisense oligonucleotide platforms. PTCT: PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved products and partnered collaboration deals.
Side-by-side fundamentals
| Metric | PRAX | PTCT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $315.80 | $75.52 | |
| Market cap as of 2026-07-31 | $8.8B | $6.2B | |
| P/E as of 2026-07-31 | n/a | 16.83 | |
| PEG as of 2026-07-31 | -0.87 | 1.20 | PRAX lower |
| Net margin as of 2026-07-31 | -2137.5% | +0.9% | PTCT higher |
| Gross margin as of 2026-07-31 | n/a | +32.6% | |
| Operating margin as of 2026-07-31 | -2340.3% | +8.9% | PTCT higher |
| ROE as of 2026-07-31 | -43.0% | +0.1% | PTCT higher |
| ROA as of 2026-07-31 | -40.2% | +0.3% | PTCT higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.03 | PRAX lower |
| Revenue growth (YoY) as of 2026-07-31 | n/a | -53.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.3% | |
| Beta as of 2026-07-31 | 2.83 | 0.98 | |
| 1-year return as of 2026-07-27 close | +433.3% | +48.3% | PRAX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.